Cowen reissued their hold rating on shares of Axovant Gene Therapies (NASDAQ:AXGT) in a report released on Tuesday, AnalystRatings.com reports.
A number of other equities research analysts have also issued reports on the stock. JMP Securities upped their target price on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the company an outperform rating in a research note on Thursday, June 6th. Zacks Investment Research lowered shares of First Bancorp from a buy rating to a hold rating in a research note on Friday, June 14th. Leerink Swann assumed coverage on shares of Axovant Gene Therapies in a research note on Friday, June 21st. They issued an outperform rating and a $5.79 target price on the stock. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Finally, HC Wainwright restated a buy rating and issued a $25.00 target price on shares of Kadmon in a research note on Tuesday, March 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $28.76.
NASDAQ:AXGT opened at $7.22 on Tuesday. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $6.16. The stock has a market cap of $151.03 million, a PE ratio of -0.90 and a beta of 1.28. Axovant Gene Therapies has a 1-year low of $3.81 and a 1-year high of $21.92.
Axovant Gene Therapies (NASDAQ:AXGT) last posted its quarterly earnings data on Tuesday, June 11th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.70) by $1.25. On average, analysts predict that Axovant Gene Therapies will post -5.71 earnings per share for the current year.
In other news, CEO Pavan Cheruvu purchased 7,500 shares of the company’s stock in a transaction on Friday, June 14th. The shares were bought at an average price of $5.21 per share, for a total transaction of $39,075.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.20% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in AXGT. Marshall Wace LLP bought a new position in shares of Axovant Gene Therapies in the first quarter valued at approximately $272,000. Primecap Management Co. CA bought a new position in shares of Axovant Gene Therapies in the first quarter valued at approximately $1,400,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Axovant Gene Therapies in the first quarter valued at approximately $6,794,000.
About Axovant Gene Therapies
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Further Reading: Different Types of Derivatives
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.